A Case Study in Neurotherapeutic Clinical Trial Design and Conduct
September 2024 New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities Early this summer, Cleveland Clinic researchers enrolled the…
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
September 2, 2024 • In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed…
Stuart Schlossman
Could CAR T cell therapy change the way we treat autoimmune diseases?
CAR T cell therapy is now being studied in autoimmune diseases, including: The immune system is the body’s natural defense…
Stuart Schlossman
MS trial to test magnetic brain stimulation for overactive bladder
Texas site now enrolling 29 women with MS and urinary tract problems Steve Bryson, PhD avatarby Steve Bryson, PhD |…
Stuart Schlossman
Racial and Ethnic Disparities in Multiple Sclerosis MRI Outcomes
Information provided by Sheila Thorne, President & CEO – Multicultural Healthcare Marketing Group Specializing in Cultural Competency Training Medically reviewed by…
Stuart Schlossman
Researchers are committed to finding solutions for everyone affected by MS — the very people who hold the key to the answers.
Information provided by: Paige B. Dalton, JD – Manager, Healthcare Provider Engagement National Multiple Sclerosis Society Professional Resource Center : National…
Stuart Schlossman
Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for MS – PubMed
https://pubmed.ncbi.nlm.nih.gov/37400245/ Gabriel Bsteh 1 2, Harald Hegen 3, Patrick Altmann 4 2, Michael Auer 3, Klaus Berek 3, Franziska Di Pauli 3, Barbara Kornek 4 2, Nik Krajnc 4 2, Fritz Leutmezer 4 2, Stefan Macher 4 2, Paulus Stefan Rommer 4 2, Karin Zebenholzer 4 2, Gudrun Zulehner 4 2, Tobias Zrzavy 4 2, Florian Deisenhammer 3, Berthold Pemp 5, Thomas…
Stuart Schlossman
Risk Factors for Multiple Sclerosis Development After Optic Neuritis Diagnosis Using a Nationwide Health Records Database
Henry C Skrehot 1, Anshul Bhatnagar 1, Austin Huang 1, Andrew G Lee Affiliations expand PMID: 37398505 PMCID: PMC10312022 (available on 2024-02-16) DOI: 10.1080/01658107.2023.2176891 Abstract Multiple sclerosis (MS) is an…
Stuart Schlossman
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Click to Subscribe for the MS Beacon eNewsletter, resources and MS education …
Stuart Schlossman
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial
Click to Subscribe for the MS Beacon eNewsletter, resources and MS education Mitzi J Williams 1, Annette F Okai 2, Anne H Cross 3, Nancy L…
Stuart Schlossman
